Trial Profile
A Prospective Observational Post-Marketing Study of Harvoni in Japanese Patients With Genotype 1 Chronic Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Sep 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 14 Sep 2017 Status changed from active, no longer recruiting to completed.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Sep 2017.